2024年12月期の業績予想は、現時点で合理的な業績予想の算定ができないため、記載されていない。Helios <4593> announced its consolidated financial results (IFRS) for the third quarter of the fiscal year ending in December 2024 on the 13th. Revenue increased by 374.2% year-on-year to 0.542 billion yen, with an operating loss of 1.976 billion yen (compared to a loss of 2.298 billion yen in the same period last year), a pre-tax loss of 4.504 billion yen (compared to a loss of 2.03 billion yen), and a quarterly loss attributable to owners of the parent company of 4.491 billion yen (compared to a loss of 2.092 billion yen).
The company group has promoted research and development in the fields of somatic stem cell regenerative pharmaceuticals and iPSC regenerative pharmaceuticals. In the somatic stem cell regenerative pharmaceuticals field, preparations are being made towards acquiring approval for the treatment drug MultiStem for Acute Respiratory Distress Syndrome (ARDS) and acute cerebral infarction, based on the results of respective clinical trials. In June 2024, a basic business partnership agreement regarding the distribution and sales of products handled by the company was concluded with Alfresa, as well as a purchase contract for the first series of ordinary bonds and the second series of ordinary bonds totaling 1.6 billion yen.
During the cumulative period of the third quarter, the total amount of research and development expenses was 1.474 billion yen (compared to 1.531 billion yen in the same period last year).
The performance financial estimates for the fiscal year ending in December 2024 are not provided as reasonable estimations cannot be calculated at this point.
